Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 12, Number 9—September 2006
Research

Fluoroquinolones and Risk for Methicillin-Resistant Staphylococcus aureus, Canada

Louiselle LeBlanc*, Jacques Pépin*Comments to Author , Krystel Toulouse*, Marie-France Ouellette*, Marie-Andrée Coulombe*, Marie-Pier Corriveau*, and Marie-Eve Alary*
Author affiliations: *University of Sherbrooke, Sherbrooke, Quebec, Canada

Main Article

Table 3

MSSA infection according to demographic, clinical, and pharmaceutical characteristics during 7,371 episodes of care*

Characteristic Crude hazard ratio (95% CI) Adjusted hazard ratio (95% CI)
Age, y
18–64 1.00 1.00
65–79 0.69 (0.41–1.18) 0.56 (0.32–0.98)‡
>80 0.29 (0.14–0.60)† 0.38 (0.18–0.83)‡
Hospital stay,§ days
1–7 1.00
8–14 2.30 (1.21–4.38)‡ NS
>15 1.74 (0.92–3.31)
Charlson comorbidity index
0 1.00
1–3 1.10 (0.51–2.38)
4–6 1.56 (0.70–3.50) NS
>7
3.58 (1.57–8.19)‡

History of
Diabetes mellitus 3.00 (1.85–4.86)† 2.24 (1.33–3.79)‡
Chronic renal failure 2.26 (1.33–3.85)‡ 1.98 (1.11–3.55)‡
Peripheral vascular disease 1.92 (1.17–3.14)‡ 1.73 (1.02–2.96)‡
Ischemic heart disease 1.37 (0.84–2.23) NS
Peptic ulcer disease 0.92 (0.40–2.14) NS
Procedures and care
ICU stay 5.40 (3.27–8.93)† 3.16 (1.78–5.63)†
Surgery 6.45 (3.87–10.76)† 4.95 (2.83–8.66)†
Tube feeding
6.74 (3.68–12.35)†
2.19 (1.12–4.29)‡
Antimicrobial drugs received
Quinolones 1.03 (0.59–1.78) NS
Cephalosporins
1st generation 2.29 (1.26–4.17)‡ NS
2nd generation 0.98 (0.50–1.93) NS
3rd generation 1.07 (0.46–2.48) NS
Macrolides 0.28 (0.04–2.00) NS
Clindamycin 2.11 (0.66–6.73) NS
IV β-lactam/β-lactam inhibitors 2.23 (1.05–4.73)‡ NS
Amoxicillin/clavulanic acid 1.15 (0.28–4.71) NS
Carbapenems 4.19 (1.30–13.52)‡ NS
Narrow-spectrum penicillins¶ 2.04 (1.06–3.92)‡ NS
Aminoglycosides 2.14 (0.92–4.98) NS
Cotrimoxazole 0.42 (0.06–3.05) NS
Metronidazole 1.26 (0.62–2.56) NS
IV vancomycin 3.30 (1.40–7.75)‡ NS
Oral vancomycin 1.01 (0.24–4.17) NS
Other drugs
Proton pump inhibitors 1.31 (0.80–2.14) NS
H2 blockers 4.31 (2.65–7.02)† NS
Corticosteroids 1.56 (0.91–2.67) NS

*MSSA, methicillin-sensitive Staphylococcus aureus; CI, confidence interval; NS, not significant; ICU, intensive care unit; IV, intravenous.
†p<0.001.
‡p<0.05.
§Duration of stay, including all admissions during that episode of care.
¶Penicillin, ampicillin, amoxicillin, cloxacillin.

Main Article

Page created: November 18, 2011
Page updated: November 18, 2011
Page reviewed: November 18, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external